ORAL PHARMACEUTICAL FORMULATIONS OF VLA-4 ANTAGONISTS

摘要

The present invention provides oral pharmaceutical formulations comprising a VLA-4 antagonist and a surfactant. In one preferred embodiment, the VLA-4 antagonist is the mono-sodium salt of (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid. The present invention also provides methods for treating and/or preventing and/or inhibiting progress of an inflammatory disease using such pharmaceutical formulations.